Needham Downgrades Revance Therapeutics to Hold
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has downgraded Revance Therapeutics (NASDAQ:RVNC) from Buy to Hold.
August 13, 2024 | 10:08 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Needham analyst Serge Belanger has downgraded Revance Therapeutics from Buy to Hold, indicating a less optimistic outlook on the stock.
The downgrade from Buy to Hold by a reputable analyst suggests a less favorable view on the stock's short-term performance, likely leading to a negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100